This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

A Case of Complex Movement Disorder Induced by Fluoxetine With Management of Dystonia by Botulinum Toxin Type A

J. Chen, PharmD, BCPS, CGP, and David M. Swope, MD

Published: February 15, 2005

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Selective serotonin reuptake inhibitors (SSRIs) have been associated with movement disorders such as akathisia, dystonia, dyskinesia, and parkinsonism.1-3 We present a case of fluoxetine-induced de novo complex movement disorder characterized by orofacial dyskinesia, jaw-closing dystonia, bruxism, and parkinsonism. Focal injections of botulinum toxin type A (BTX-A) were required to treat the dystonic features.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 66

Quick Links: